RxDoctor Payments Data

Anton Svetlanov

Neurology · Edison, NJNPI 1346667599

Payments from drug & device makers

$9,774in general payments, 2019–2025

Across 590 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AbbVie$891
  • Neurocrine Biosciences, Inc.$793
  • Biogen$743
  • Teva Pharmaceuticals USA, Inc.$565
  • Boston Scientific$533
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$9,70799%
  • Education$671%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,774 in reported general payments places this provider in the 65th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$95,438
Medicare patients
358
Services billed
1,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate73$420,312
IngrezzaValbenazine Tosylate51$405,840
RebifInterferon Beta-1a/Albumin22$289,429
AustedoDeutetrabenazine22$218,788
RytaryCarbidopa/Levodopa95$168,270
TecfideraDimethyl Fumarate12$110,869
NourianzIstradefylline15$40,064
NeuproRotigotine32$35,541
RexultiBrexpiprazole20$31,562
Carbidopa-LevodopaCarbidopa/Levodopa801$21,240
LamictalLamotrigine14$10,442
Rasagiline Mesylate36$9,210
Aimovig AutoinjectorErenumab-Aooe13$9,075
Carbidopa-Levodopa ErCarbidopa/Levodopa170$8,614
AmantadineAmantadine Hcl126$7,645

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$274$420,31273 claims
Neurocrine Biosciences, Inc.Ingrezza$793$405,84051 claims
EMD Serono, Inc.Rebif$59$289,42922 claims
Teva Pharmaceuticals USA, Inc.Austedo$565$218,78822 claims
Amneal Pharmaceuticals LLCRytary$522$168,27095 claims
BiogenTecfidera$743$110,86912 claims
Kyowa Kirin, Inc.Nourianz$221$40,06415 claims
UCB, Inc.Neupro$364$35,54132 claims
Otsuka America Pharmaceutical, Inc.Rexulti$77$31,56220 claims
PfizerDilantin$21$1,84612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 521 neurology providers in New Jersey.

Other neurology in Edison

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →